• About Us
  • About Us
  • People
• Teaching
  • Presentations
  • BME 7132
• Research
  • Research & Development
  • Clinical
• Publications
  • Abstracts
  • Journal Articles
  • Conferences/Seminars
• GXMO
  • Didatic
  • Clinical

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study of one-year duration followed by 2 years of open-label treatment to determine the safety and efficacy of orally administered 2.5 mg or 5.0 mg risedronate in children > 4 to < 16 years old with osteogenesis imperfecta

In collaboration with Wright State University and Miami Valley Hospital of Dayton, OH, we studied OI diagnosed children, 4 to 16 years old, during a three-year osteogenesis imperfecta study. The medicine to be tested is risedronate and belongs to a group of medicines called bisphosphonates. This medicine has been shown to increase bone density in adults, while maintaining bone structure and quality, and therefore makes bones less likely to break.

Recruitment for the study is closed.

Updated January, 2013